Document is current
Any future updates will be listed below
-
Authors
Tawbi, Hussein A https://orcid.org/0000-0003-1942-851X
Robert, Caroline
Brase, Jan C
Gusenleitner, Daniel
Gasal, Eduard
Garrett, James
Savchenko, Alexander
Görgün, Güllü
Flaherty, Keith T
Ribas, Antoni
Dummer, Reinhard https://orcid.org/0000-0002-2279-6906
Schadendorf, Dirk
Long, Georgina V
Nathan, Paul D
Ascierto, Paolo A https://orcid.org/0000-0002-8322-475X
-
Clinical Trials BETA
Clinical trials referenced in this document:
nct02967692 at ClinicalTrials.govnct02967692 at ClinicalTrials.govDocuments that mention this clinical trial
Spartalizumab or placebo in combination with dabrafenib and trametinib in patients with <i>BRAF</i> V600-mutant melanoma: exploratory biomarker analyses from a randomized phase 3 trial (COMBI-i)
https://doi.org/10.1136/jitc-2021-004226
Update on BRAF and MEK inhibition for treatment of melanoma in metastatic, unresectable, and adjuvant settings
https://doi.org/10.1080/14740338.2019.1607289
Evolving impact of long-term survival results on metastatic melanoma treatment
https://doi.org/10.1136/jitc-2020-000948
Efficacy of novel immunotherapy regimens in patients with metastatic melanoma with germline <i>CDKN2A</i> mutations
https://doi.org/10.1136/jmedgenet-2018-105610
nct02130466 at ClinicalTrials.govDocuments that mention this clinical trial
Spartalizumab or placebo in combination with dabrafenib and trametinib in patients with <i>BRAF</i> V600-mutant melanoma: exploratory biomarker analyses from a randomized phase 3 trial (COMBI-i)
https://doi.org/10.1136/jitc-2021-004226
Update on BRAF and MEK inhibition for treatment of melanoma in metastatic, unresectable, and adjuvant settings
https://doi.org/10.1080/14740338.2019.1607289
Evolving impact of long-term survival results on metastatic melanoma treatment
https://doi.org/10.1136/jitc-2020-000948
Efficacy of novel immunotherapy regimens in patients with metastatic melanoma with germline <i>CDKN2A</i> mutations
https://doi.org/10.1136/jmedgenet-2018-105610
nct02908672 at ClinicalTrials.govDocuments that mention this clinical trial
Spartalizumab or placebo in combination with dabrafenib and trametinib in patients with <i>BRAF</i> V600-mutant melanoma: exploratory biomarker analyses from a randomized phase 3 trial (COMBI-i)
https://doi.org/10.1136/jitc-2021-004226
Update on BRAF and MEK inhibition for treatment of melanoma in metastatic, unresectable, and adjuvant settings
https://doi.org/10.1080/14740338.2019.1607289
Response to: ‘Checkpoint inhibitor-induced polymyalgia rheumatica controlled by cobimetinib, a MEK 1/2 inhibitor’ by Chan and Bass
https://doi.org/10.1136/annrheumdis-2018-213682
KEYNOTE-022 part 3: a randomized, double-blind, phase 2 study of pembrolizumab, dabrafenib, and trametinib in <i>BRAF</i>-mutant melanoma
https://doi.org/10.1136/jitc-2020-001806
P863 KEYNOTE-022 parts 4 and 5: pembrolizumab plus trametinib for patients with solid tumors or BRAF wild-type melanoma
https://doi.org/10.1136/lba2019.16
nct02967692 at ClinicalTrials.govDocuments that mention this clinical trial
Spartalizumab or placebo in combination with dabrafenib and trametinib in patients with <i>BRAF</i> V600-mutant melanoma: exploratory biomarker analyses from a randomized phase 3 trial (COMBI-i)
https://doi.org/10.1136/jitc-2021-004226
Update on BRAF and MEK inhibition for treatment of melanoma in metastatic, unresectable, and adjuvant settings
https://doi.org/10.1080/14740338.2019.1607289
Efficacy of nivolumab plus relatlimab versus BRAF/MEK inhibitors for first-line treatment of <i>BRAF</i> -mutant advanced melanoma: A matching-adjusted indirect comparison
https://doi.org/10.1136/bmjonc-2025-000912
Response to: ‘Checkpoint inhibitor-induced polymyalgia rheumatica controlled by cobimetinib, a MEK 1/2 inhibitor’ by Chan and Bass
https://doi.org/10.1136/annrheumdis-2018-213682
Evolving impact of long-term survival results on metastatic melanoma treatment
https://doi.org/10.1136/jitc-2020-000948
307 Atezolizumab plus vemurafenib and cobimetinib provides favorable survival outcomes in patients with high tumor mutation burden and proinflammatory gene signature in the phase 3 IMspire150 study
https://doi.org/10.1136/jitc-2020-sitc2020.0307
301 Association of response with survival outcomes with atezolizumab in combination with vemurafenib and cobimetinib in the phase 3 IMspire150 study
https://doi.org/10.1136/jitc-2020-sitc2020.0301
Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of melanoma, version 3.0
https://doi.org/10.1136/jitc-2023-006947
nct02967692 at ClinicalTrials.govDocuments that mention this clinical trial
Spartalizumab or placebo in combination with dabrafenib and trametinib in patients with <i>BRAF</i> V600-mutant melanoma: exploratory biomarker analyses from a randomized phase 3 trial (COMBI-i)
https://doi.org/10.1136/jitc-2021-004226
Update on BRAF and MEK inhibition for treatment of melanoma in metastatic, unresectable, and adjuvant settings
https://doi.org/10.1080/14740338.2019.1607289
Evolving impact of long-term survival results on metastatic melanoma treatment
https://doi.org/10.1136/jitc-2020-000948
Efficacy of novel immunotherapy regimens in patients with metastatic melanoma with germline <i>CDKN2A</i> mutations
https://doi.org/10.1136/jmedgenet-2018-105610
Documents that mention this clinical trial
Spartalizumab or placebo in combination with dabrafenib and trametinib in patients with <i>BRAF</i> V600-mutant melanoma: exploratory biomarker analyses from a randomized phase 3 trial (COMBI-i)
https://doi.org/10.1136/jitc-2021-004226
Update on BRAF and MEK inhibition for treatment of melanoma in metastatic, unresectable, and adjuvant settings
https://doi.org/10.1080/14740338.2019.1607289
Evolving impact of long-term survival results on metastatic melanoma treatment
https://doi.org/10.1136/jitc-2020-000948
Efficacy of novel immunotherapy regimens in patients with metastatic melanoma with germline <i>CDKN2A</i> mutations
https://doi.org/10.1136/jmedgenet-2018-105610
-
Funding
Funding for this research was provided by:
Novartis Pharmaceuticals Corporation
- License Information
